levobunolol
Trade name: betagan
Approved
Dec 19, 1985
Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 adrenergic receptors. Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in its potential for direct myocardial depression. Accordingly, the levo isomer, levobunolol, is used. Levobunolol does not have significant local anesthetic (membrane-stabilizing) or intrinsic sympathomimetic activity. Levobunolol, sold under the brand name Betagan, has been shown to be an active agent in lowering elevated as well as normal intraocular pressure (IOP) whether or not accompanied by glaucoma. Levobunolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease sinus bradycardia; second and third-degree atrioventricular block; overt cardiac failure cardiogenic shock; or hypersensitivity to any component of these products. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 12 marketing orgs
Timeline
1980s
- Dec 19, 1985
Allergan — Earliest FDA Approval
- Dec 19, 1985
Allergan — NDA Secondary Org
- Dec 19, 1985
Allergan — NDA Organization
- Dec 19, 1985
SmithKline Beckman — NDA Secondary Org
- Jun 28, 1989
SmithKline Beecham — NDA Secondary Org
1990s
- Mar 4, 1994
Bausch & Lomb — Marketing Organization
- Oct 28, 1996
Alcon — Marketing Organization
- Oct 28, 1996
Sandoz — Marketing Organization
- Oct 28, 1996
Novartis — Marketing Organization
- Oct 28, 1996
Nestle — Marketing Organization
- Oct 28, 1996
Chartwell Pharmaceuticals — Marketing Organization
- Oct 29, 1996
Akorn, Inc. — Marketing Organization
- Oct 29, 1996
Epic Pharma Llc — Marketing Organization
2000s
- Aug 3, 2000
Apotex — Marketing Organization
Indications
Mechanism of action
- Beta-1 adrenergic receptorANTAGONIST
ADRB1 antagonist
- Beta-2 adrenergic receptorANTAGONIST
ADRB2 antagonist
Approval history
- approvedDec 19, 1985
Chemistry & pharmacology
SMILES
CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O- Mol. weight
- 291.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL1201237 ↗
- WikipediaLevobunolol ↗
- NCATSG6317AOI7K ↗
- ChEMBLCHEMBL1201177 ↗
Also known as
- akbeta
- akbeta
- betagan
- betagan
- betagan
- betagan
- (-)-bunolol
- (-)-bunolol
- levobunolol
- levobunolol
- levobunolol
- levobunolol
- levobunolol
- levobunolol
- levobunolol
- levobunolol
- levobunolol
- levobunolol
- levobunolol hcl
- levobunolol hcl
- levobunolol hcl
- levobunolol hydrochloride
- levobunolol hydrochloride
- levobunolol hydrochloride
- levobunolol hydrochloride
- levobunololum
- levobunololum
- (s)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2h)-naphthalenone
- (s)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2h)-naphthalenone
- w-7000a
- w-7000a
Organizations
Marketing (15)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Akorn, Inc. | For profit | MKTG | Oct 29, 1996 |
| Alcon | For profit | MKTG | Oct 28, 1996 |
| Allergan | For profit | NDA2 | Dec 19, 1985 |
| Allergan | For profit | NDA | Dec 19, 1985 |
| Apotex | For profit | MKTG | Aug 3, 2000 |
| Bausch & Lomb | For profit | MKTG | Mar 4, 1994 |
| Bausch & Lomb | For profit | SYN | Mar 4, 1994 |
| Chartwell Pharmaceuticals | For profit | MKTG | Oct 28, 1996 |
| Epic Pharma Llc | For profit | MKTG | Oct 29, 1996 |
| Nestle | For profit | MKTG | Oct 28, 1996 |
| Novartis | For profit | MKTG | Oct 28, 1996 |
| Sandoz | For profit | MKTG | Oct 28, 1996 |
| Sandoz | For profit | SYN | Oct 28, 1996 |
| SmithKline Beckman | For profit | NDA2 | Dec 19, 1985 |
| SmithKline Beecham | For profit | NDA2 | Jun 28, 1989 |